Project Grant HT94252410243
Award Date
5/1/24
Completion Date
4/30/27
Dollars Obligated
$1.5M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Buffalo, NY 14263, USA
Similar Awards
This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,561,500.00 to Health Research, Inc. at Roswell Park Cancer Center to conduct research targeting prostate cancer metabolic vulnerabilities in the bone microenvironment. The goal is to develop new approaches to circumvent lethal metastatic disease. The 3-year award period runs from September 15, 2023 to September 14, 2026. As a non-profit research organization,...
The U.S. Defense Health Agency awarded a $1,513,169 Project Grant to Health Research, Inc. to support the "LEVERAGING POLYAMINE METABOLISM TO TARGET EPIGENOMIC ADAPTABILITY AND LINEAGE PLASTICITY IN PROSTATE CANCER" research project under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, beginning on April 1, 2024, aims to develop innovative approaches for treating prostate cancer by targeting tumor metabolism and epigenetic mechanisms. As a...
The Defense Health Agency awarded a $1,561,500 Project Grant to Health Research, Inc. Roswell Park Division for the period of March 15, 2023 through March 14, 2026. The grant will support research into slow-cycling prostate cancer cells in therapy resistance, disease relapse, and metastasis. This award is being made under the Military Medical Research and Development program (CFDA 12.420). This program aims to transform military and public health through innovative medical research solutions for...
This Project Grant award from the U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $171,700 to Health Research, Inc. to conduct research on the "Mechanism of Anti-SEMA4D Therapy Reversal of Immunosuppression in the Prostate Tumor Microenvironment." The 2-year research project aims to investigate novel cancer immunotherapy approaches to treat prostate cancer. As a non-profit organization, Health Research, Inc. collaborates extensively...
Health Research, Inc. Inc Roswell Park Division Health Research Division (the Division) was awarded a $693,987 project grant from the Defense Health Agency through the Military Medical Research and Development program (CFDA 12.420). The grant will fund cancer immunotherapy research from June 1, 2023 through May 31, 2026. Specifically, the Division will investigate strategies to counter solid tumor antigen immune escape using CAR T cell therapies. As a past recipient of Defense Health Agency...
Health Research, Inc. Roswell Park Division received a $559,647 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research using microfluidic lung cancer models. The two-year award, made on June 1, 2023 and set to conclude on May 31, 2025, will support investigating novel drug resistance mechanisms in lung cancer through "Microfluidic Lung Cancer On A Chip" models. As a past recipient of Defense...
This Project Grant award of $695,386.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Health Research, Inc. (Roswell Park Division) to investigate translation dysregulation in metastatic breast cancer. The project aims to evaluate the implications of this phenomenon for disease outcomes and immunotherapy responses. The award period runs from March 1, 2024 to February 28, 2027. As a prime grantee,...
Health Research, Inc. Roswell Park Division received a $780,750 project grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on mechanisms of immune suppression and potential therapies. The three-year award, made on April 1, 2023, will support investigation into how the protein neuritin mediates reprogramming of myeloid cell populations and its role in immune suppression. Through this research, the awardee aims...
This $1,000,000.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by Health Research, Inc. Inc Roswell Park Division Health Research (DBA Health Research-Roswell Park Cancer Institute Division) to target the natural immunosuppressive capabilities of endogenous beta-adrenergic neural pathways. The goal is to prolong vascularized composite allograft (VCA) graft survival and reduce toxicity risks. The...
This $260,250 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research on the role of the SLC45A3-ELK4 chimera as a molecular determinant of prostate cancer health disparities. The primary awardee, Health Research, Inc., will conduct this biomedical research at their Roswell Park Division facility in Buffalo, New York over a 2-year period from March 2025 to March 2027. The research aims to advance understanding...